Fresh Tracks Therapeutics, Inc. announced its Board of Directors has appointed Andrew Sklawer, the Company's current President, as Chief Executive Officer (CEO), effective February 1, 2023. Mr. Sklawer will succeed Rob Brown, who has led the company as CEO since 2019 and is retiring. Mr. Brown will continue to serve as a non-executive member of the Board of Directors and a special advisor to the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9294 USD | -2.17% | +3.27% | +5.72% |
15/03 | Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+5.72% | 5.55M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- FRTX Stock
- News Fresh Tracks Therapeutics, Inc.
- Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023